These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 24875081)
1. Learning from exceptional drug responders. Mullard A Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081 [No Abstract] [Full Text] [Related]
2. The role of the National Cancer Institute in drug development. Doroshow J Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997 [No Abstract] [Full Text] [Related]
6. Slow start to phase 0 as researchers debate value. Twombly R J Natl Cancer Inst; 2006 Jun; 98(12):804-6. PubMed ID: 16788150 [No Abstract] [Full Text] [Related]
7. Can single-patient investigational new drug studies hurry slow trains to the fast track? Chenoweth D Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594 [TBL] [Abstract][Full Text] [Related]
8. American society of clinical oncology - 45th annual meeting. Part 1. Gale S IDrugs; 2009 Jul; 12(7):401-3. PubMed ID: 19579154 [No Abstract] [Full Text] [Related]
9. American society of clinical oncology - 45th annual meeting. Part 2. Lakeram M; Kibble A IDrugs; 2009 Jul; 12(7):404-8. PubMed ID: 19579155 [No Abstract] [Full Text] [Related]
10. Discontinued drugs in 2008: oncology drugs. Williams R Expert Opin Investig Drugs; 2009 Nov; 18(11):1581-94. PubMed ID: 19663760 [TBL] [Abstract][Full Text] [Related]
11. Japan works to shorten "drug lag," boost trials of new drugs. Sinha G J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160 [No Abstract] [Full Text] [Related]
12. Translational research in the National Cancer Institute's cooperative groups. Symmans WF Clin Adv Hematol Oncol; 2014 Nov; 12(11):785-7. PubMed ID: 25674720 [No Abstract] [Full Text] [Related]
20. The erosion of research integrity: the need for culture change. Ellis LM Lancet Oncol; 2015 Jul; 16(7):752-4. PubMed ID: 26149871 [No Abstract] [Full Text] [Related] [Next] [New Search]